QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.073486v1 312/1/83    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, J. Articles by Liu, C. Search for Related Content PubMed PubMed Citation Articles by Chen, J. Articles by Liu, C.

CELLULAR AND MOLECULAR

Pharmacological Characterization of Relaxin-3/INSL7 Receptors GPCR135 and GPCR142 from Different Mammalian Species

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., San Diego, California (J.C., C.K., S.W.S., P.B., D.N., T.W.L., C.L.); and Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden (E.E., R.S.)

Relaxin-3 has recently been identified as a ligand for two structurally related G-protein-coupled receptors, human GPCR135 and GPCR142. This current study reports the characterization of mouse and rat GPCR135 as well as GPCR142 from mouse, monkey, cow, and pig at the molecular and pharmacological levels. Mouse and rat GPCR135 exhibit high homology (>85%) to the human GPCR135 and have very similar pharmacological properties to that of the human GPCR135. Human and mouse/rat relaxin-3 both bind to and activate mouse, rat, and human GPCR135 at high affinity with IC₅₀ or EC₅₀ values close to 0.5 nM. In contrast, the mouse GPCR142 is less well conserved (74% homology) with human GPCR142. The rat GPCR142 gene was found to be a pseudogene. We further cloned GPCR142 genes from monkey, cow, and pig and found that they are highly homologous (>84%) to human GPCR142. Pharmacological characterization of GPCR142 from different species demonstrated that relaxin-3 binds to GPCR142 from different species at high affinity (IC₅₀ < 5 nM). However, relaxin-3 does not stimulate a Ca²⁺ response in cells coexpressing G₁₆ and mouse GPCR142, whereas it does for cells expressing GPCR142 from other species tested. Our results suggest that GPCR142 may have a diminished role as a receptor for relaxin-3 in rodents, or perhaps GPCR142 functions as a receptor for another ligand in nonrodents. Boels and Schaller recently reported bradykinin as a ligand for GPCR142 (also known as GPR100). In this report, we demonstrate that bradykinin activates neither GPCR135 nor GPCR142, whereas relaxin-3 does.

Address correspondence to: Dr. Changlu Liu, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 3210 Merryfield Row, San Diego, CA 92121. E-mail: cliu9{at}prdus.jnj.com

This article has been cited by other articles:

				B. M. McGowan, S. A. Stanley, J. Donovan, E. L. Thompson, M. Patterson, N. M. Semjonous, J. V. Gardiner, K. G. Murphy, M. A. Ghatei, and S. R. Bloom Relaxin-3 stimulates the hypothalamic-pituitary-gonadal axis Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E278 - E286. [Abstract] [Full Text] [PDF]

				C. Kuei, S. Sutton, P. Bonaventure, C. Pudiak, J. Shelton, J. Zhu, D. Nepomuceno, J. Wu, J. Chen, F. Kamme, et al. R3(B{Delta}23 27)R/I5 Chimeric Peptide, a Selective Antagonist for GPCR135 and GPCR142 over Relaxin Receptor LGR7: IN VITRO AND IN VIVO CHARACTERIZATION J. Biol. Chem., August 31, 2007; 282(35): 25425 - 25435. [Abstract] [Full Text] [PDF]

				B. M. McGowan, S. A. Stanley, N. E. White, A. Spangeus, M. Patterson, E. L. Thompson, K. L. Smith, J. Donovan, J. V. Gardiner, M. A. Ghatei, et al. Hypothalamic mapping of orexigenic action and Fos-like immunoreactivity following relaxin-3 administration in male Wistar rats Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E913 - E919. [Abstract] [Full Text] [PDF]

				J. Novak, L. J. Parry, J. E. Matthews, L. J. Kerchner, K. Indovina, K. Hanley-Yanez, K. D. Doty, D. O. Debrah, S. G. Shroff, and K. P. Conrad Evidence for local relaxin ligand-receptor expression and function in arteries FASEB J, November 1, 2006; 20(13): 2352 - 2362. [Abstract] [Full Text] [PDF]

				J. D. Silvertown, J. S. Walia, A. J. Summerlee, and J. A. Medin Functional Expression of Mouse Relaxin and Mouse Relaxin-3 in the Lung from an Ebola Virus Glycoprotein-Pseudotyped Lentivirus via Tracheal Delivery Endocrinology, August 1, 2006; 147(8): 3797 - 3808. [Abstract] [Full Text] [PDF]

				B. M. C. McGowan, S. A. Stanley, K. L. Smith, N. E. White, M. M. Connolly, E. L. Thompson, J. V. Gardiner, K. G. Murphy, M. A. Ghatei, and S. R. Bloom Central Relaxin-3 Administration Causes Hyperphagia in Male Wistar Rats Endocrinology, August 1, 2005; 146(8): 3295 - 3300. [Abstract] [Full Text] [PDF]

				C. Liu, J. Chen, C. Kuei, S. Sutton, D. Nepomuceno, P. Bonaventure, and T. W. Lovenberg Relaxin-3/Insulin-Like Peptide 5 Chimeric Peptide, a Selective Ligand for G Protein-Coupled Receptor (GPCR)135 and GPCR142 over Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 7 Mol. Pharmacol., January 1, 2005; 67(1): 231 - 240. [Abstract] [Full Text] [PDF]